Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-04-16
Target enrollment:
Participant gender:
Summary
RATIONALE:
The combination of anti-angiogenic targeted therapy with neoadjuvant chemotherapy has been
shown to further improve the pathologic response rate for HER2-negative breast cancer
patients. Apatinib is a highly potent human vascular endothelial growth factor receptor 2
(VEGFR2) tyrosine kinase inhibitor that has been independently developed in China, and it can
exert anti-angiogenic effects by inhibiting VEGFR2. It is unknown whether giving combination
neoadjuvant chemotherapy together with apatinib is more effective in treating patients with
nonmetastatic HER2-negative breast cancer.
PURPOSE:
To explore the efficacy and safety of apatinib added to weekly paclitaxel and cisplatin
neoadjuvant therapy for HER-2 negative breast cancer patients